Joe M. Butler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Joe M. Butler has a total of 263 co-authors. Here are the top co-authors by number of shared publications:
- Tom van der Poll
Center of Experimental and Molecular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands
12 shared publications - Hessel Peters-Sengers
Centre for Infection and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
9 shared publications - Alex F. de Vos
Center for Infection and Molecular Medicine, Amsterdam University Medical Center, University of Amsterdam, 1105AZ Amsterdam, The Netherlands
8 shared publications - Alex R. Schuurman
Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, University of Amsterdam and VU University Amsterdam
6 shared publications - Michel van Weeghel
Laboratory Genetic Metabolic Diseases, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands
6 shared publications Tom van der Poll
Centre for Infection and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
6 shared publications
Latest Publications
- Open Access
- 9 July 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Programmed death-ligand 1 links with inflammatory and endothelial activation in pneumonia
Background: Soluble programmed death-ligand 1 (sPD-L1) is often considered a marker of immunosuppression, proposed to reflect PD-1/PD-L1 signalling on immune cells. We aimed to investigate this premise and characterised plasma sPD-L1-associated immune responses in community-acquired pneumonia (CAP). Methods: Plasma sPD-L1 and 60 biomarkers reflecting inflammation, vascular response, coagulation and cytokine/chemokine release were measured in CAP patients within 24 h after admission to a general hospital ward. Associations were analysed using both univariate and multivariable models. In patient subgroups, immune cell PD-1/PD-L1 was assessed by spectral flow cytometry and blood transcriptomes by RNA sequencing. Results: CAP patients (n=226) were stratified into tertiles based on sPD-L1 levels. Admission disease severity scores were similar across groups. In-hospital mortality only occurred in the highest sPD-L1 tertile and in a continuous analysis sPD-L1 independently predicted 28-day mortality (overall 4.4%). Higher sPD-L1 was linked to plasma biomarker changes indicating increased systemic inflammation, cytokine release, and endothelial activation. sPD-L1 did not correlate with PD-L1 expression on monocytes or dendritic cells, nor with PD-L1 gene expression in whole blood. sPD-L1 did not associate with immunosuppression markers (IL-10, monocyte HLA-DR, and PD-1 on T cells). In patients with high sPD-L1, blood transcriptomes showed enrichment of haemostasis, endothelial activation, and systemic inflammation, but not of programmed cell death pathways. Conclusions: In patients hospitalised with CAP plasma sPD-L1 does not reflect immune cell PD-L1 expression or immunosuppression, but rather systemic inflammation and endothelial activation.
- 9 July 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Open AccessProgrammed death-ligand 1 links with inflammatory and endothelial activation in pneumonia
Background: Soluble programmed death-ligand 1 (sPD-L1) is often considered a marker of immunosuppression, proposed to reflect PD-1/PD-L1 signalling on immune cells. We aimed to investigate this premise and characterised plasma sPD-L1-associated immune responses in community-acquired pneumonia (CAP). Methods: Plasma sPD-L1 and 60 biomarkers reflecting inflammation, vascular response, coagulation and cytokine/chemokine release were measured in CAP patients within 24 h after admission to a general hospital ward. Associations were analysed using both univariate and multivariable models. In patient subgroups, immune cell PD-1/PD-L1 was assessed by spectral flow cytometry and blood transcriptomes by RNA sequencing. Results: CAP patients (n=226) were stratified into tertiles based on sPD-L1 levels. Admission disease severity scores were similar across groups. In-hospital mortality only occurred in the highest sPD-L1 tertile and in a continuous analysis sPD-L1 independently predicted 28-day mortality (overall 4.4%). Higher sPD-L1 was linked to plasma biomarker changes indicating increased systemic inflammation, cytokine release, and endothelial activation. sPD-L1 did not correlate with PD-L1 expression on monocytes or dendritic cells, nor with PD-L1 gene expression in whole blood. sPD-L1 did not associate with immunosuppression markers (IL-10, monocyte HLA-DR, and PD-1 on T cells). In patients with high sPD-L1, blood transcriptomes showed enrichment of haemostasis, endothelial activation, and systemic inflammation, but not of programmed cell death pathways. Conclusions: In patients hospitalised with CAP plasma sPD-L1 does not reflect immune cell PD-L1 expression or immunosuppression, but rather systemic inflammation and endothelial activation.
- Open Access
- 28 October 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (6) , 2500335
The proteomic landscape of blood monocytes in community-acquired pneumonia
Introduction: Monocytes play a pivotal role in the regulation of inflammation and pathogen clearance during infection. Knowledge of the human monocyte proteome during infection is limited. We present a comprehensive proteome profile of blood monocytes from patients with community-acquired pneumonia (CAP), one of the most common infectious diseases, and controls without infection. Methods: Monocytes were purified from blood of patients with CAP within 16 h of admission to a general hospital ward and from controls matched for sex, age and comorbidities. Monocyte proteins were measured using liquid chromatography/mass spectrometry. The transcriptome was analysed in the same samples by RNA sequencing. Monocytes were stimulated with lipopolysaccharide for 24 h, after which cytokines were measured in the supernatant. Results: We analysed the monocyte proteome of 34 CAP patients and 23 controls. Out of 7315 annotated proteins, 1340 (18.3%) were differentially abundant between groups. Functional enrichment analyses revealed a marked downregulation of mitochondrial respiration processes in patient monocytes; pathways pertaining to cell cycle, cytokine signalling and cell death were upregulated in patient monocytes. Monocyte mRNA levels correlated poorly with the abundance of corresponding proteins and associated functional pathways, raising caution regarding interpretation of functionality estimates based on transcriptome analyses. Differential expression of monocyte proteins had functional and clinical implications as indicated by associations with cytokine production capacity, disease severity and time to clinical stability. Conclusion: This study provides a publicly available monocyte protein atlas that can serve as a resource for future research on monocyte functions during infection.
- 28 October 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (6) , 2500335
Open AccessThe proteomic landscape of blood monocytes in community-acquired pneumonia
Introduction: Monocytes play a pivotal role in the regulation of inflammation and pathogen clearance during infection. Knowledge of the human monocyte proteome during infection is limited. We present a comprehensive proteome profile of blood monocytes from patients with community-acquired pneumonia (CAP), one of the most common infectious diseases, and controls without infection. Methods: Monocytes were purified from blood of patients with CAP within 16 h of admission to a general hospital ward and from controls matched for sex, age and comorbidities. Monocyte proteins were measured using liquid chromatography/mass spectrometry. The transcriptome was analysed in the same samples by RNA sequencing. Monocytes were stimulated with lipopolysaccharide for 24 h, after which cytokines were measured in the supernatant. Results: We analysed the monocyte proteome of 34 CAP patients and 23 controls. Out of 7315 annotated proteins, 1340 (18.3%) were differentially abundant between groups. Functional enrichment analyses revealed a marked downregulation of mitochondrial respiration processes in patient monocytes; pathways pertaining to cell cycle, cytokine signalling and cell death were upregulated in patient monocytes. Monocyte mRNA levels correlated poorly with the abundance of corresponding proteins and associated functional pathways, raising caution regarding interpretation of functionality estimates based on transcriptome analyses. Differential expression of monocyte proteins had functional and clinical implications as indicated by associations with cytokine production capacity, disease severity and time to clinical stability. Conclusion: This study provides a publicly available monocyte protein atlas that can serve as a resource for future research on monocyte functions during infection.
- Open Access
- 28 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10461
Role of Myeloid Cell Glucose Transporter 1 in the Host Response During Pneumonia Caused by Streptococcus pneumoniae
During infection, myeloid cells are subjected to a fast increase in energy demand. Glucose transporter 1 (GLUT1) is a key mediator of glucose metabolism, especially for glycolysis. The present study aimed to investigate GLUT1 expression in monocytes and neutrophils from patients with community-acquired pneumonia (CAP) and to determine the functional role of GLUT1 in the responsiveness during pneumonia evoked in mice by Streptococcus (S.) pneumoniae, the most common causative pathogen in CAP. GLUT1 expression in monocytes and neutrophils of patients and controls was determined by RNA sequencing and flow cytometry analysis. Myeloid cell-specific GLUT1-deficient mice and controls were intranasally infected with S. pneumoniae, after which bacterial loads, lung pathology, and cytokine levels were analyzed. GLUT1 gene expression was upregulated in monocytes from CAP patients in comparison to matched subjects without infection, and protein expression was increased upon ex vivo activation. In neutrophils, GLUT1 mRNA levels were significantly upregulated in CAP patients, but protein levels were not altered. Surprisingly, myeloid-specific GLUT1-deficient mice displayed an unaltered host response during pneumococcal pneumonia. These data suggest that GLUT1 may contribute to immune responses of myeloid cells during CAP, but that its role may be superseded by other mechanisms during pneumococcal pneumonia.
- 28 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10461
Open AccessRole of Myeloid Cell Glucose Transporter 1 in the Host Response During Pneumonia Caused by Streptococcus pneumoniae
During infection, myeloid cells are subjected to a fast increase in energy demand. Glucose transporter 1 (GLUT1) is a key mediator of glucose metabolism, especially for glycolysis. The present study aimed to investigate GLUT1 expression in monocytes and neutrophils from patients with community-acquired pneumonia (CAP) and to determine the functional role of GLUT1 in the responsiveness during pneumonia evoked in mice by Streptococcus (S.) pneumoniae, the most common causative pathogen in CAP. GLUT1 expression in monocytes and neutrophils of patients and controls was determined by RNA sequencing and flow cytometry analysis. Myeloid cell-specific GLUT1-deficient mice and controls were intranasally infected with S. pneumoniae, after which bacterial loads, lung pathology, and cytokine levels were analyzed. GLUT1 gene expression was upregulated in monocytes from CAP patients in comparison to matched subjects without infection, and protein expression was increased upon ex vivo activation. In neutrophils, GLUT1 mRNA levels were significantly upregulated in CAP patients, but protein levels were not altered. Surprisingly, myeloid-specific GLUT1-deficient mice displayed an unaltered host response during pneumococcal pneumonia. These data suggest that GLUT1 may contribute to immune responses of myeloid cells during CAP, but that its role may be superseded by other mechanisms during pneumococcal pneumonia.
- Open Access
- 29 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Effect of the gut microbiota-derived tryptophan metabolite indole-3-acetic acid in pneumonia
Gut microbiota influence the severity of pneumonia by producing metabolites that enhance systemic and pulmonary immune responses. Preclinical studies suggested that gut microbiota-derived indoles have protective effects against numerous diseases, including influenza and abdominal infections. However, the precise role of tryptophan metabolites during pneumonia is unknown. Here, we perform translational analyses in a large general-population cohort (n = 13,464), critically ill patients with severe community-acquired pneumonia (CAP; n = 158; NCT01905033), a randomized human intervention trial on antibiotic-mediated microbiota modulation (NCT03051698), and mice to investigate the effects of tryptophan metabolites, specifically indole-3-acetic acid (IAA), on pneumonia. In the population-based cohort, baseline IAA is associated with a higher risk of future hospital admission for pneumonia (cause-specific hazard ratio 1.15, 95% confidence interval 1.09-1.22 p < 0.0001). In patients with severe CAP higher levels of IAA are associated with increased mortality, independent from potential confounders (hazard ratio 1.30 per log2 increase, 95% confidence interval 1.02-1.68, p = 0.037). In a mouse model of bacterial pneumonia, IAA supplementation aggravates pulmonary damage while reducing systemic dissemination, which is mediated by the aryl hydrocarbon receptor (AhR) and increased release of reactive oxygen species from neutrophils. In summary, these findings from general population and severe pneumonia cohorts, and murine pneumonia experiments, show that the gut microbiota-derived tryptophan metabolite IAA affects pneumonia, suggesting that various indoles may have diverging, context-dependent effects.
- 29 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Open AccessEffect of the gut microbiota-derived tryptophan metabolite indole-3-acetic acid in pneumonia
Gut microbiota influence the severity of pneumonia by producing metabolites that enhance systemic and pulmonary immune responses. Preclinical studies suggested that gut microbiota-derived indoles have protective effects against numerous diseases, including influenza and abdominal infections. However, the precise role of tryptophan metabolites during pneumonia is unknown. Here, we perform translational analyses in a large general-population cohort (n = 13,464), critically ill patients with severe community-acquired pneumonia (CAP; n = 158; NCT01905033), a randomized human intervention trial on antibiotic-mediated microbiota modulation (NCT03051698), and mice to investigate the effects of tryptophan metabolites, specifically indole-3-acetic acid (IAA), on pneumonia. In the population-based cohort, baseline IAA is associated with a higher risk of future hospital admission for pneumonia (cause-specific hazard ratio 1.15, 95% confidence interval 1.09-1.22 p < 0.0001). In patients with severe CAP higher levels of IAA are associated with increased mortality, independent from potential confounders (hazard ratio 1.30 per log2 increase, 95% confidence interval 1.02-1.68, p = 0.037). In a mouse model of bacterial pneumonia, IAA supplementation aggravates pulmonary damage while reducing systemic dissemination, which is mediated by the aryl hydrocarbon receptor (AhR) and increased release of reactive oxygen species from neutrophils. In summary, these findings from general population and severe pneumonia cohorts, and murine pneumonia experiments, show that the gut microbiota-derived tryptophan metabolite IAA affects pneumonia, suggesting that various indoles may have diverging, context-dependent effects.
- Open Access
- 24 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9309
The Sirt1 Activator SRT1720 Mitigates Human Monocyte Activation and Improves Outcome During Gram-Negative Pneumosepsis in Mice
Community-acquired pneumonia (CAP) is a leading cause of death, with mortality linked to an unbalanced host response. Sirtuin (Sirt)1, a histone deacetylase, regulating metabolism and epigenetics, may be fundamental in activating the innate immune response. Sirt1 mRNA expression was significantly reduced in monocytes from CAP patients (n = 76) upon admission compared to healthy controls (n = 42), with levels returning to normal after 30 days. Pharmacological activation of Sirt1 with SRT1720 decreased LPS- and K. pneumoniae-induced IL-6 release in primary human monocytes and decreased NF-κB activation in THP1 cells. In a mouse K. pneumoniae pneumosepsis model, SRT1720 strongly reduced neutrophil influx and degranulation markers in bronchoalveolar lavage fluid, lowered pulmonary concentrations of IL-6 and TNF-α, and reduced lung pathology scores. Simultaneously, it reduced neutrophil content in liver tissue and plasma transaminase levels, alongside a trend toward reduced liver necrosis. Plasma IL-6 and TNF-α were significantly lower in SRT1720-treated mice at 42 h. Finally, while SRT1720 did not impact bacterial loads in the lungs, it reduced bacterial burden in blood, with a similar trend observed in liver homogenates. In conclusion, the Sirt1 activator SRT1720 exerts anti-inflammatory effects on human monocytes, reduces local and systemic inflammation and organ injury, and diminishes bacterial dissemination in murine pneumosepsis.
- 24 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9309
Open AccessThe Sirt1 Activator SRT1720 Mitigates Human Monocyte Activation and Improves Outcome During Gram-Negative Pneumosepsis in Mice
Community-acquired pneumonia (CAP) is a leading cause of death, with mortality linked to an unbalanced host response. Sirtuin (Sirt)1, a histone deacetylase, regulating metabolism and epigenetics, may be fundamental in activating the innate immune response. Sirt1 mRNA expression was significantly reduced in monocytes from CAP patients (n = 76) upon admission compared to healthy controls (n = 42), with levels returning to normal after 30 days. Pharmacological activation of Sirt1 with SRT1720 decreased LPS- and K. pneumoniae-induced IL-6 release in primary human monocytes and decreased NF-κB activation in THP1 cells. In a mouse K. pneumoniae pneumosepsis model, SRT1720 strongly reduced neutrophil influx and degranulation markers in bronchoalveolar lavage fluid, lowered pulmonary concentrations of IL-6 and TNF-α, and reduced lung pathology scores. Simultaneously, it reduced neutrophil content in liver tissue and plasma transaminase levels, alongside a trend toward reduced liver necrosis. Plasma IL-6 and TNF-α were significantly lower in SRT1720-treated mice at 42 h. Finally, while SRT1720 did not impact bacterial loads in the lungs, it reduced bacterial burden in blood, with a similar trend observed in liver homogenates. In conclusion, the Sirt1 activator SRT1720 exerts anti-inflammatory effects on human monocytes, reduces local and systemic inflammation and organ injury, and diminishes bacterial dissemination in murine pneumosepsis.
- Open Access
- 7 August 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (5) , 2402208
Butyrate-producing gut bacterium Faecalibacterium prausnitzii protects against bacterial pneumonia
Background: Gut microbiota play a protective role against pneumonia in mice, probably by producing the immunomodulatory short-chain fatty acid butyrate. Yet, butyrate has limited potential for clinical use due to its challenging handling in practice. We performed mouse experiments and translational analyses to determine whether butyrate-producing gut commensals, Faecalibacterium prausnitzii and Anaerobutyricum soehngenii , could provide protection against bacterial pneumonia and serve as next-generation probiotics. Methods: We pre-treated C57BL/6J mice with butyrate, F. prausnitzii (recently reclassified as F. duncaniae ) or A. soehngenii , and subsequently infected them intranasally with Klebsiella pneumoniae . To assess the relevance in humans, we assessed associations between rectal levels of Faecalibacterium , immune responses and clinical outcomes in 115 patients with community-acquired pneumonia (CAP) and in a separate validation cohort. Results: Pre-treatment with F. prausnitzii , but not A. soehngenii , protected mice against bacterial pneumonia, as reflected by reduced bacterial growth and dissemination, lessened organ damage, and dampened inflammation. Similar to butyrate pre-treatment, F. prausnitzii resulted in reduced pulmonary interleukin (IL)-6 and CXCL1. In humans, gut Faecalibacterium was decreased during CAP compared to matched controls. CAP patients with higher gut Faecalibacterium levels had lower IL-6-producing capacity and downregulated inflammatory gene expression. Higher intestinal Faecalibacterium levels were associated with better clinical outcomes in independent cohorts of CAP and critically ill patients, which remained significant when controlled for potential confounders. Conclusion: This is the first study showing that the gut commensal F. prausnitzii provides protection against bacterial pneumonia and has translational potential. This motivates future studies investigating the clinical potential of F. prausnitzii as a novel probiotic for pneumonia.
- 7 August 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (5) , 2402208
Open AccessButyrate-producing gut bacterium Faecalibacterium prausnitzii protects against bacterial pneumonia
Background: Gut microbiota play a protective role against pneumonia in mice, probably by producing the immunomodulatory short-chain fatty acid butyrate. Yet, butyrate has limited potential for clinical use due to its challenging handling in practice. We performed mouse experiments and translational analyses to determine whether butyrate-producing gut commensals, Faecalibacterium prausnitzii and Anaerobutyricum soehngenii , could provide protection against bacterial pneumonia and serve as next-generation probiotics. Methods: We pre-treated C57BL/6J mice with butyrate, F. prausnitzii (recently reclassified as F. duncaniae ) or A. soehngenii , and subsequently infected them intranasally with Klebsiella pneumoniae . To assess the relevance in humans, we assessed associations between rectal levels of Faecalibacterium , immune responses and clinical outcomes in 115 patients with community-acquired pneumonia (CAP) and in a separate validation cohort. Results: Pre-treatment with F. prausnitzii , but not A. soehngenii , protected mice against bacterial pneumonia, as reflected by reduced bacterial growth and dissemination, lessened organ damage, and dampened inflammation. Similar to butyrate pre-treatment, F. prausnitzii resulted in reduced pulmonary interleukin (IL)-6 and CXCL1. In humans, gut Faecalibacterium was decreased during CAP compared to matched controls. CAP patients with higher gut Faecalibacterium levels had lower IL-6-producing capacity and downregulated inflammatory gene expression. Higher intestinal Faecalibacterium levels were associated with better clinical outcomes in independent cohorts of CAP and critically ill patients, which remained significant when controlled for potential confounders. Conclusion: This is the first study showing that the gut commensal F. prausnitzii provides protection against bacterial pneumonia and has translational potential. This motivates future studies investigating the clinical potential of F. prausnitzii as a novel probiotic for pneumonia.
- Open Access
A bioenergetic basis for multiorgan dysfunction in sepsis
Sepsis is a life-threatening multiorgan dysfunction that develops from a maladaptive host response to infection 1 . With an estimated 49 million cases per year and ∼11 million related deaths 2 , sepsis is a global WHO health priority 3 . Failure to overcome sepsis morbidity and lethality 4,5 calls for alternative therapeutic approaches 6–8 . Here we report that adipocyte lipolysis is vital to prevent the pathogenesis of sepsis in mice. This protective response is evolutionary conserved, producing a plasma lipidomic profile 9,10 that reflects on the severity of clinical sepsis. Mechanistically, adipocyte lipolysis fuels energy metabolism to sustain adaptive thermoregulation to infection, via insulin production and insulin receptor (INSR) signaling in adipocytes. This metabolic-based defense strategy does not impact on bacterial burden, establishing disease tolerance to infection 11–14 . In conclusion, adipocyte lipolysis induces insulin to rewire energy metabolism and support organ function in response to infection.
Open AccessA bioenergetic basis for multiorgan dysfunction in sepsis
Sepsis is a life-threatening multiorgan dysfunction that develops from a maladaptive host response to infection 1 . With an estimated 49 million cases per year and ∼11 million related deaths 2 , sepsis is a global WHO health priority 3 . Failure to overcome sepsis morbidity and lethality 4,5 calls for alternative therapeutic approaches 6–8 . Here we report that adipocyte lipolysis is vital to prevent the pathogenesis of sepsis in mice. This protective response is evolutionary conserved, producing a plasma lipidomic profile 9,10 that reflects on the severity of clinical sepsis. Mechanistically, adipocyte lipolysis fuels energy metabolism to sustain adaptive thermoregulation to infection, via insulin production and insulin receptor (INSR) signaling in adipocytes. This metabolic-based defense strategy does not impact on bacterial burden, establishing disease tolerance to infection 11–14 . In conclusion, adipocyte lipolysis induces insulin to rewire energy metabolism and support organ function in response to infection.
- Open Access
- 11 June 2025
- Published by Elsevier in EBioMedicine
- Vol. 117, 105799
Pathogen-specific host response in critically ill patients with blood stream infections: a nested case–control study
- 11 June 2025
- Published by Elsevier in EBioMedicine
- Vol. 117, 105799
Open AccessPathogen-specific host response in critically ill patients with blood stream infections: a nested case–control study
- Open Access
- 23 January 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 65 (4) , 2400592
The blood transcriptional response in patients developing intensive care unit-acquired pneumonia
Background: Immune response dysregulation has been implicated in the development of intensive care unit (ICU)-acquired pneumonia. We aimed to determine differences in the longitudinal blood transcriptional response between patients who develop ICU-acquired pneumonia (cases) and those who do not (controls).Methods: We performed a case–cohort study in mechanically ventilated trauma and surgery patients with ICU stays >2 days, enrolled in 30 hospitals across Europe. We collected blood for RNA sequencing at baseline, day 7 and (in cases) the day of pneumonia diagnosis. We performed gene set enrichment analysis and analysed longitudinal gene expression changes using linear mixed models. External validation was performed using an independent trauma cohort.Results: We enrolled 113 cases and 115 controls, with similar baseline characteristics. At baseline (median 2 days after ICU admission), cases showed upregulated gene pathways relating to innate immunity, haemostasis and metabolism, and downregulated adaptive immune pathways. These changes persisted at the day of pneumonia diagnosis (median 6 days, compared to day 7 in controls). In the longitudinal comparison, cases exhibited enhanced upregulation of innate immunity, adaptive immunity and haemostasis pathways, along with enhanced downregulation of metabolism pathways, relative to controls (all p<0.00001, except haemostasis p<0.05). These findings were largely externally validated. Cases had higher quantitative sepsis response signature scores (p<0.001), reflective of immune dysregulation.Conclusion: Patients developing ICU-acquired pneumonia exhibit distinct blood transcriptional responses shortly after ICU admission and in the subsequent path to pneumonia, suggestive of broad immune dysfunction with both immunosuppressive and inflammatory features.
- 23 January 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 65 (4) , 2400592
Open AccessThe blood transcriptional response in patients developing intensive care unit-acquired pneumonia
Background: Immune response dysregulation has been implicated in the development of intensive care unit (ICU)-acquired pneumonia. We aimed to determine differences in the longitudinal blood transcriptional response between patients who develop ICU-acquired pneumonia (cases) and those who do not (controls).Methods: We performed a case–cohort study in mechanically ventilated trauma and surgery patients with ICU stays >2 days, enrolled in 30 hospitals across Europe. We collected blood for RNA sequencing at baseline, day 7 and (in cases) the day of pneumonia diagnosis. We performed gene set enrichment analysis and analysed longitudinal gene expression changes using linear mixed models. External validation was performed using an independent trauma cohort.Results: We enrolled 113 cases and 115 controls, with similar baseline characteristics. At baseline (median 2 days after ICU admission), cases showed upregulated gene pathways relating to innate immunity, haemostasis and metabolism, and downregulated adaptive immune pathways. These changes persisted at the day of pneumonia diagnosis (median 6 days, compared to day 7 in controls). In the longitudinal comparison, cases exhibited enhanced upregulation of innate immunity, adaptive immunity and haemostasis pathways, along with enhanced downregulation of metabolism pathways, relative to controls (all p<0.00001, except haemostasis p<0.05). These findings were largely externally validated. Cases had higher quantitative sepsis response signature scores (p<0.001), reflective of immune dysregulation.Conclusion: Patients developing ICU-acquired pneumonia exhibit distinct blood transcriptional responses shortly after ICU admission and in the subsequent path to pneumonia, suggestive of broad immune dysfunction with both immunosuppressive and inflammatory features.
- Open Access
Effect of mesenchymal stem cells on the host response in severe community-acquired pneumonia
Mesenchymal stem cells (MSC) have immune regulatory properties that may ameliorate pathophysiological processes in sepsis. We determined the effect of allogeneic adipose-derived MSCs (Cx611) on the host response during sepsis due to community-acquired bacterial pneumonia (CABP) by measuring 29 plasma biomarkers and blood transcriptomes at six time points in 82 patients randomised to two intravenous infusions of Cx611 or placebo. Cx611 treatment enhanced several endothelial cell and procoagulant response plasma biomarkers, and led to increased expression of pathways related to innate immunity, haemostasis and apoptosis. Cx611 infusion in sepsis due to CABP is associated with broad host response alterations.
Open AccessEffect of mesenchymal stem cells on the host response in severe community-acquired pneumonia
Mesenchymal stem cells (MSC) have immune regulatory properties that may ameliorate pathophysiological processes in sepsis. We determined the effect of allogeneic adipose-derived MSCs (Cx611) on the host response during sepsis due to community-acquired bacterial pneumonia (CABP) by measuring 29 plasma biomarkers and blood transcriptomes at six time points in 82 patients randomised to two intravenous infusions of Cx611 or placebo. Cx611 treatment enhanced several endothelial cell and procoagulant response plasma biomarkers, and led to increased expression of pathways related to innate immunity, haemostasis and apoptosis. Cx611 infusion in sepsis due to CABP is associated with broad host response alterations.